Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exciting update! Scot Cave is now with PetVivo Holdings, Inc. as Field Veterinary Business Development Manager. Watch $PETV! @PetVivo
PETV: delisted from the Nasdaq to the OTC:
https://otce.finra.org/otce/dailyList?viewType=Additions
why bullish
Extreme caution here! Price ran up on hype of starting clinical trials for humans for OAK. The market is littered with failed attempts of companies that had far better solutions and they still failed. They will require well over $100 million for all the required pre-clinical and P1, 2 and multiple 3 trials. And the time to completion will definitely not be quick. This is a MINIMUM OF TEN YEARS. PETV has market cap of only about $30 million and they will have to raise over $100 million. what do you think will happen to the share price with that kind of dilution? Yes. . . .we will see many price drops and multiple reverse splits as the company tries to raise money. And short interests know this so I can guarantee that they will be shorting this and driving the price down and down and down. Just take a look at the record of Adam Feuerstein. He broke AMPE that had a much better OAK solution and now the shares are almost worthless after 14 years. And the CEO is one of these know it all arrogant types that is in for a ride to hell. VERY STRONG SELL IMO!
The Company’s management team in cooperation with its human advisory task force anticipates regulatory plans to be completed for new human products implementing the Biomatrix Particulate Technology in the first part of calendar year 2024. The products for human use will be manufactured by PetVivo in its state-of-the-art manufacturing facility in Edina, Minnesota, which is anticipated to be opened in the fourth quarter of 2023.
It's easy, to be honest when you don't say anything. They have an association with a really bad guy, Rich Carozza. He has been with every bad BD on the street. Imay have heard that he is under SEC and FBI investigation. Not sure what he is doing with PETV but it's never good. He is a really bad guy. Beware. IMO
$PETV Live on the Emerging Growth Conference in 30 Minutes
Registration link to interact with the company live here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167551494
$PETV Live on the Emerging Growth Conference Jan 19
Registration link to interact live with the company here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167540089
What is the strike price on the company’s warrants?
Congratulations John Lai on your growth in the markets!!! Good man!
PETV - Friday Rundown, Monday Expectations
Replay $PETV Emerging Growth Conference.
Link to the video is here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166165192
Next Conference October 13
Register Here:
https://goto.webcasts.com/starthere.jsp?ei=1487781&tp_key=e2bca7d62c&sti=twitter
Who do you want to see present?
Tell us here:
www.EmergingGrowth.com/Conference
EGC 17 Replay:
$CANB
$PBIO
$GNTW
$AWX / $AWG
$PETV
$UCASU
$CLSH
$MARK
$CYDY
$PETV Live on the Emerging Growth Conference in 30 minutes!
The Link to Register to Interact Live with the CEO's is here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166135334
Companies Presenting:
$UCASU
$CLSH
$MARK
$CYDY
Presenting now or Previously:
$CANB
$PBIO
$GNTW
$AWG / $AWS / $AWP / $AWX
$PETV Emerging Growth Conference 17 Starts in 1 hour!
The Link to Register to Interact Live with the CEO's is here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166135334
Companies Presenting:
$CANB
$PBIO
$GNTW
$AWG / $AWS / $AWP / $AWX
$PETV
$UCASU
$CLSH
$MARK
$CYDY
$PETV PetVivo CEO Live on the Emerging Growth Conference on September 29, 2021
Registration link here to interact Live:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=166052950
Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference
$PETV Replay Emerging Growth Conference 14
Get the link
and...
Register for the next Conference on 9/1 here...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165547337
Who do you want to see present?
EGC 14 Presenters for Replay:
$NSAV - VirtuaBroker
$RYAH $RYAHF
$PETV
$ACXP
$PBIO
$TOMDF
$GRYN
$INND
$SNMN
$WNBD
$PETV Live on the Emerging Growth Conference in 30 minutes!
Link to watch the Conference here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165497793
Other Companies Presenting:
$ACXP
$PBIO
$TOMDF
$GRYN
$INND
$SNMN
$WNBD
Presented Earlier:
$NSAV
$RYAH $RYAHF
$PETV Live on the Emerging Growth Conference this Wednesday August 18, 2021.
The registration link so you can watch the live presentation is here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165458105
$PETV PetVivo Congratulations on the NASDAQ Uplist! CEO Live on the Emerging Growth Conference on August 18, 2021
Registration Link here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165396738
Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference
PETV moved to the Nasdaq from the OTC:
https://otce.finra.org/otce/dailyList?viewType=Deletions
$PETV PetVivo Presenting Live on the Emerging Growth Conference on August 18, 2021
Registration Link Here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165369149
Who else would you like to see?
email:
Conference@EmergingGrowth.com
or
Call the number here:
http://EmergingGrowth.com/Conference
PETV: effective Dec. 30,2020 a one for 4 reverse split:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
ANOTHER RS coming. Tomorrow at the bell this ticker has a 1 for 4 RS. Hell...they just pulled a RS a year ago.
Share holders on 12/30 won't be able to sell until well into the first week of Jan, maybe later.
10,000 shares become 2500. Nice..............
NEWS: $PETV nScrypt Bioprints PetVivo® Biomaterial for Orthopedic Implants
Orlando, Florida, Oct. 20, 2020 (GLOBE NEWSWIRE) -- nScrypt is excited to announce the successful bioprinting of PetVivo ® Holdings’ biomaterial, using nScrypt’s 3D Bio-Fabrication Tool (BAT). The nScrypt BAT technology was able to easily 3D ...
Got this from PETV - nScrypt Bioprints PetVivo® Biomaterial for Orthopedic Implants
PETV a nine for ten reverse split:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
$PETV - PetVivo Up 102% Last Week on $3 Price Target Issued
PetVivo’s Holdings, Inc. (PETV: OTCQB) - CEO, John Lai, discusses the new and revolutionary treatment of osteoarthritis by administering PetVivo’s injectable product
See the video here:
News out --- PetVivo Holdings, Inc. Featured in New Research Update
Press Release | 09/26/2019
MINNEAPOLIS, MN, Sept. 26, 2019 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB:PETV), an emerging biomedical device company, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company.
The updated report provides an overview of recent events, new initiatives, and the company’s valuation relative to its peer group. The sponsored research update also carries a rating and a price target and can be accessed at its partner site, www.GoldmanResearch.com.
Marble Arch Research notes that, “With a number of competitive advantages in the space, a deep product pipeline and IP portfolio, combined with a clever financial model, we believe that the Company can enjoy hockey-stick type sales growth in the next 2-3 years. Plus, its new technology licensing for CBD use could prove to be a sleeper and a very profitable engine for PetVivo. Our target is based upon a 5.5x sales P/S multiple, similar to its peer group, and affirmed by a Net Present Value (NPV) calculation. In our view, the current price reflects an attractive entry point.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of eighteen patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs and horses called Kush® is scheduled for launch later this fiscal year.
The Company recently exclusively licensed its mucoadhesive technology to a strategic partner, Emerald Organic Products, Inc., for use of CBD in the human nutraceutical market. The Company will also be seeking additional licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
John Lai
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
I found this on their website...very interesting.
One Injection Restored Mobility in Their Lives for Years – $PETV
https://petvivo.com/
Interesting Development.
Emerald Organic Products, Inc. (EMOR) Announces Exclusive Licensing Agreement With PetVivo Holdings Inc. (PETV).
“In the right hands, this product has the potential to revolutionize the vitamin and CBD market place and we are confident we found the right team partner in Emerald.”
http://marijuanastockreview.com/emerald-organic-products-inc-emor-announces-exclusive-licensing-agreement-with-petvivo-holdings-inc-petv/
Anyone have an idea if PETCO joint goop is viable and soon to report initial sales?
The term someone shed a light down the crack.
Wow.
The term "fallen between the cracks" comes to mind. Studying now.
Percentage drop appears like a typical toxic unwinding, but there's no volume so doubt that was the cause.
MINNEAPOLIS, Sept. 05, 2018 (GLOBE NEWSWIRE) -- OTCPINK: PETV PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company, is pleased to announce the addition of Mr. Michael Haider and Mr. Joel Hapke.
Michael Haider has over 40 years of medical business, finance and management experience, most recently as Co-Founder and CEO of CytoMedical Design Group LLC, a company focused on blood-based stem cell research. Haider was President and CEO of BioE LLC, BioE, Inc. and he was President and owner of Kodiak Restoration, a dental and medical equipment service company; president and co-founder of PulseTrend, Inc., a maker of ambulatory blood pressure devices; and vice president and CFO of PPT Vision, a producer of machine vision technologies. Prior to these endeavors, Haider held a variety of positions in corporate finance at Medtronic, Inc., a leading provider of medical devices. Recent Honors: He was named one of Twin Cities-based Finance and Commerce’s “Innovators of The Year” in 2003. In 2006 Minnesota Tekne Award, Emerging Biotechnology Company category and Twin Cities Business, 2007 Biosciences Success Stories. 2009 to current a member of the National Marrow Foundation (“Be the Match”) New Technology Council, since 2007 to current an annual presenter of stem cell business strategies to the University of Minnesota School of Pharmacy.
Mr. Haider commented, “I am looking forward to working with the PetVivo team toward implementing PetVivo’s vision and exciting technology toward improved patient outcomes in veterinary and future human therapies. “
Mr. Joel Hapke has over 30 years of combined experience in clinical laboratory science, medical device and diagnostic assay development. Joel has been with CytoMedical Design, LLC and BioE, Inc. for the past 18 years as the Manager of Manufacturing, Analytical and Process Engineering. Prior to coming to BioE and CytoMedical, Joel was employed by QuanTech Ltd. As the Systems Integration Coordinator, working with both engineering and chemistry personnel to develop a clinical assay platform utilizing Surface Plasmon Resonance (SPR) for a Point of Care medical device.
“The addition of Mr. Haider and Joel Hapke, working alongside our current staff in our manufacturing and research area, gives PetVivo an ability for testing, revising and innovation with little outside contracting of services. Our intension is to continue on this path, creating better manufacturing standards and efficiencies along with expanding the use of our current products.” Stated Wes Hayne, CEO.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s
lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
Forward-Looking commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
CONTACT:
Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
Main: 962-405-6216
Direct: (763) 443-7272
$PETV
Good morning Murdoc
Ready to make your cash?!
$$$$
PETV owns a bunch of patents and from 10q for period ending 12/31/17 they only have/had? one convertible note for $110k and $557k cash on hand
https://backend.otcmarkets.com/otcapi/company/sec-filings/12706882/content/html
http://petvivo.com/patents/
Nice catch Hippo! Great to see you
PETV can break out easy.
19,189,748 OS a/o 4/30/18
1,355,182 Float a/o 4/30/18
Insiders holding vast majority of the issued shares
John Lai, Co-founder, President & Chairman and intern CFO, Mr. Lai has over 30 years of senior operations and financial experience and has served as CEO at Rovvr, Inc. & Genesis Capital Group, Inc., President at Viper Powersports, Inc. and CFO at Buyitnow.com. Mr. Lai has extensive experience in capital structure, financial analysis, business formation, mergers, acquisitions and driving production revenue growth.
PETV
Nice! Lots of nice green candles! $PETV
Followers
|
25
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1151
|
Created
|
09/04/12
|
Type
|
Free
|
Moderators |
Market Value1 | $1,349,150 | a/o Feb 21, 2014 |
Shares Outstanding | 122,650,000 | a/o Feb 14, 2014 |
Float | 37,150,000 | a/o Jun 04, 2013 |
Authorized Shares | 400,000,000 | a/o May 21, 2013 |
Par Value | 0.001 |
John Dolan, General Counsel at PetVivo, Inc. since inception. Mr. Dolan has over 25 years of experience as a legal professional, patent attorney, corporate council and senior executive as an expert in the utilization of IP to capitalize and commercialize entities ranging from early stage to the Fortune 500. He has also served as a patent examiner at the U.S. Patent and Trademark Office.
John Howard, Director at PetVivo, Inc. since inception. Mr. Howard is an entrepreneurial executive with over 25 years business experience. His accomplishments include founding and managing companies in enterprise software, cyber security, software-as-a-service (SaaS), and digital publishing. Mr. Howard has special expertise in sales and marketing, business development, and M&A.Location
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |